Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease
Authors
Keywords
-
Journal
Expert Review of Neurotherapeutics
Volume 14, Issue 9, Pages 973-986
Publisher
Informa UK Limited
Online
2014-08-01
DOI
10.1586/14737175.2014.945522
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Is there still any hope for amyloid-based immunotherapy for Alzheimerʼs disease?
- (2014) Francesco Panza et al. CURRENT OPINION IN PSYCHIATRY
- Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward
- (2014) Francesco Panza et al. Expert Review of Clinical Immunology
- Amyloid-ß-directed immunotherapy for Alzheimer's disease
- (2014) L. Lannfelt et al. JOURNAL OF INTERNAL MEDICINE
- Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014
- (2014) L. S. Schneider et al. JOURNAL OF INTERNAL MEDICINE
- Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?
- (2014) Eric Karran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease
- (2014) A. M. Fagan et al. Science Translational Medicine
- The A4 Study: Stopping AD Before Symptoms Begin?
- (2014) R. A. Sperling et al. Science Translational Medicine
- 2013 Alzheimer's disease facts and figures
- (2013) Alzheimers & Dementia
- Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive?
- (2013) Haythum O Tayeb et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Intravenous immunoglobulin and Alzheimer’s disease: what now?
- (2013) David A Loeffler Journal of Neuroinflammation
- Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
- (2013) Richard Dodel et al. LANCET NEUROLOGY
- Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
- (2013) Victor L Villemagne et al. LANCET NEUROLOGY
- Immunotherapy for Alzheimer’s disease: hoops and hurdles
- (2013) Cynthia A Lemere Molecular Neurodegeneration
- Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial
- (2013) S.M. Mills et al. REVUE NEUROLOGIQUE
- Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
- (2013) Krista L Moulder et al. Alzheimers Research & Therapy
- Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
- (2013) Jens Moreth et al. Immunity & Ageing
- Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
- (2012) Martin Farlow et al. Alzheimers & Dementia
- Brain injury biomarkers are not dependent on β-amyloid in normal elderly
- (2012) David S. Knopman et al. ANNALS OF NEUROLOGY
- Amyloid-β–Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau
- (2012) Rahul S. Desikan et al. ARCHIVES OF NEUROLOGY
- Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
- (2012) Henrik Zetterberg ARCHIVES OF NEUROLOGY
- Gantenerumab for the treatment of Alzheimer's disease
- (2012) Julien Delrieu et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
- (2012) Bruno P Imbimbo et al. Expert Review of Clinical Immunology
- An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A
- (2012) O. Adolfsson et al. JOURNAL OF NEUROSCIENCE
- Preclinical Alzheimer disease—the challenges ahead
- (2012) Reisa A. Sperling et al. Nature Reviews Neurology
- Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease
- (2012) D. S. Knopman et al. NEUROLOGY
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
- (2012) Randall J. Bateman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Marilyn S. Albert et al. Alzheimers & Dementia
- Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
- (2011) Victor L. Villemagne et al. ANNALS OF NEUROLOGY
- An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease
- (2011) Clifford R. Jack et al. ANNALS OF NEUROLOGY
- Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
- (2011) Susanne Ostrowitzki ARCHIVES OF NEUROLOGY
- Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab
- (2011) Francesco Panza et al. Current Alzheimer Research
- Antibody-based therapy in Alzheimer's disease
- (2011) Refik Pul et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease
- (2010) Eric R. Siemers et al. CLINICAL NEUROPHARMACOLOGY
- 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
- (2010) Juha O Rinne et al. LANCET NEUROLOGY
- Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy
- (2009) Roy O. Weller et al. ACTA NEUROPATHOLOGICA
- -Amyloid Monomers Are Neuroprotective
- (2009) M. L. Giuffrida et al. JOURNAL OF NEUROSCIENCE
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
- (2009) S. Salloway et al. NEUROLOGY
- Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain
- (2008) D. Boche et al. BRAIN
- Rapid Microglial Response Around Amyloid Pathology after Systemic Anti-A Antibody Administration in PDAPP Mice
- (2008) J. Koenigsknecht-Talboo et al. JOURNAL OF NEUROSCIENCE
- In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification
- (2008) Stefan Steidl et al. MOLECULAR IMMUNOLOGY
- Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse
- (2008) Peter Seubert et al. Neurodegenerative Diseases
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More